Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MENOPUR vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Induction of ovulation in patients with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Off-label: Treatment of male hypogonadotropic hypogonadism (in combination with human chorionic gonadotropin)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Metabolism is not fully characterized; renally excreted as intact protein.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 10-20% bound to plasma proteins, primarily albumin.
92% bound primarily to albumin
Approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous or intramuscular: Approximately 70-80% due to partial local degradation; oral bioavailability is negligible (<1%).
Oral: 85% with high first-pass effect; IM: 100%
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to limited data, consider risk of fluid retention.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) as metabolism is hepatic; use with caution in Child-Pugh class B.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not indicated; no established pediatric dosing.
Not approved for pediatric use.
Not indicated for geriatric patients; no dosing recommendations.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
MENOPUR should only be used by physicians who are experienced in infertility diagnosis and management. Use may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and result in pulmonary embolism, stroke, ovarian torsion, or death. Use should be avoided in women with a high baseline FSH level indicating primary ovarian failure.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian Hyperstimulation Syndrome (OHSS) - risk minimized by monitoring estradiol levels and ultrasound; discontinue if severe.,Multiple pregnancy - high risk; counseling is required.,Ovarian enlargement - usually resolves without treatment.,Pulmonary embolism and arterial thromboembolism - especially in severe OHSS.,Ovarian torsion - consider in patients with severe OHSS.,Ectopic pregnancy - increased risk in patients with tubal disease.,Congenital malformations - incidence similar to natural conception.,Ovarian neoplasms - no definitive causal link, but caution.
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to menotropins or any component.,High baseline FSH indicating primary ovarian failure.,Uncontrolled thyroid or adrenal dysfunction.,Organic intracranial lesion (e.g., pituitary tumor).,Abnormal uterine bleeding of undetermined origin.,Ovarian cysts or enlargement of undetermined origin (not due to PCOS).,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine).,Pregnancy and lactation.
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No clinically relevant food interactions have been reported. Patients should maintain a normal balanced diet. Grapefruit and grapefruit juice are not known to interact with menotropins. No restriction on caffeine or dairy products.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects, congenital heart defects, and multiple anomalies, likely related to the underlying infertility and assisted reproductive technology rather than direct teratogenicity. Second and third trimester risks include preterm labor, low birth weight, and perinatal mortality due to multiple gestation and ovarian hyperstimulation syndrome (OHSS).
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Menotropins are not indicated during lactation due to lack of data. It is unknown if menotropins are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during therapy. M/P ratio is unknown.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Menopur is contraindicated during pregnancy. If inadvertent exposure occurs, no dose adjustment is applicable as therapy is discontinued upon pregnancy confirmation. Pharmacokinetic changes in pregnancy (increased plasma volume, altered hormone levels) are not relevant since the drug is not used during gestation.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
MENOPUR (menotropins) is a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) used for ovulation induction and controlled ovarian stimulation. Monitor ovarian response with ultrasound and estradiol levels to minimize risk of ovarian hyperstimulation syndrome (OHSS). Adjust dose based on antral follicle count and prior response. For IVF, concomitant gonadotropin-releasing hormone (Gn RH) antagonist or agonist is typically used to prevent premature LH surge. Administer intramuscularly or subcutaneously; reconstitute immediately before use. Multifetal pregnancy rates are high; counsel patients accordingly.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
MENOPUR is a hormone injection used to help your ovaries produce multiple eggs. It is given as a shot under the skin or into a muscle. Your doctor will show you how to prepare and inject the medication. Do not shake the vial after mixing. Use each vial only once and discard any unused medicine.,Common side effects include injection site reactions (pain, redness, swelling), ovarian enlargement, abdominal discomfort, and mood swings. Serious risks include ovarian hyperstimulation syndrome (OHSS) with symptoms like sudden severe abdominal pain, nausea, vomiting, and rapid weight gain. Notify your doctor immediately if you experience these.,You will have frequent blood tests and vaginal ultrasounds to monitor your response. Stick to the schedule and do not change doses without consulting your doctor.,There is a high chance of multiple pregnancy (twins, triplets, etc.). Discuss the risks and implications with your doctor.,Avoid alcohol and smoking during treatment. No specific food restrictions, but maintain a balanced diet to support overall health.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MENOPUR vs ANTAGONATE, answered by our medical review team.
MENOPUR is a Gonadotropin that works by Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MENOPUR and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MENOPUR is: 225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MENOPUR and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MENOPUR is classified as Category C. Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.